INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE, C9
Reports Third Quarter 2026 Financial Results and Provides Business Update
To Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
Completes Acquisition of Forte Biosciences, Inc.
ALKIVIA Study Topline Results August 17, 2026
Press Release August 3, 2026
Material disclosure
Annual and Transition Report of Foreign Private Issuers
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Tender Offer Statement by Third Party
Submission Upload
Correspondence